Loading clinical trials...
Loading clinical trials...
A pilot trial of triheptanoin, a natural compound able to promote anaplerotic mitochondrial metabolism, for the preventative treatment of migraine.
To test the ability of a daily 3-month treatment with triheptanoin to prevent migraine attacks in 10 migraine patients. This is an open, non-randomized pilot trial that might justify a placebo-controlled trial, if there are at least 50% of patients with ≥50% reduction in attack frequency.
Age
18 - 65 years
Sex
FEMALE
Healthy Volunteers
No
Start Date
June 1, 2016
Primary Completion Date
November 1, 2016
Completion Date
November 1, 2016
Last Updated
May 27, 2016
10
ESTIMATED participants
Triheptanoin
DRUG
Lead Sponsor
University of Liege
NCT07018713
NCT06641466
NCT04715685
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions